RWE’s Moment: What Covid-19 means for you

Why medical and commercial leaders need to align on evidence strategy to meet customer demands

Driven by the Covid-19 pandemic, a new hunger for insight has spiked the appetite for real-world evidence across our industry.

Regulators have turned to RWE in the search for an effective Covid-19 treatment and to pass new emergency use approvals. Innovative payers and providers now use data sources once considered “untested” (e.g., wearable devices, smartphone diagnostic tools) to collect evidence about their populations, understand symptom progression, and better detect at-risk individuals. While HTAs are increasingly incorporating RWE into value assessments to inform price and access decisions.

And don’t be mistaken. This hunger is here to stay.

You must strengthen your evidence generation strategies now to meet these growing demands or fall behind adaptive competition. Yet optimizing internal RWE strategies and functions is easier said than done. Covid-19 has not erased the evidence generation challenges faced before. You must then go beyond the status quo of piecemeal RWE efforts and cross-functional collaboration to overcome legacy data and operational silos, and to improve efficacy and impact of RWE studies.

Advisory Board’s Madhavi Kasinadhuni is moderating a cross-functional panel of RWE leaders from Amgen, Takeda, Vertex, and Sanofi during a webinar on September 24. Attendees will learn:

  • New industry-wide RWE use cases accelerated by Covid-19—and what new practices are here to stay
  • Four priorities for RWE to support market adoption that medical, HEOR, market access, key accounts, and R&D leaders can align on
  • How organizational models for RWE generation can both help and hinder cross-functional collaboration across the product lifecycle

Register now

Download our most popular RWE research 
Fill out the form to download our briefing: How to Use EHR-Based Real World Data to Demonstrate Value. Note if you'd like to receive pricing and membership options from a sales representative.



Madhavi Kasinadhuni
Managing Director of Healthcare Ecosystem Research
Advisory Board
Connect with Madhavi on LinkedIn


5 types of data health care leaders are leveraging to answer key Covid-19 questions

Many leaders are doubling down on investments in a wide array of data sources—such as EHRs, wearables, and tech platforms—to develop robust clinical evidence to answer critical questions regarding Covid-19.

Download our free resource as we outline five new data sources that clinical leaders are turning to, to answer five key Covid-19 questions.

About Advisory Board

For more than 40 years, we've helped executives and future leaders in health care work smarter and faster by providing provocative insights, actionable strategies, and practical tools to support execution.

With 40+ years of experience, a team of 250+ experts, and a network of 4,900+ member organizations that span the payer, provider, and supplier industries, we support life sciences firms’ commercial and medical leaders with research and educational resources that develop market strategy, enrich customer insight, and more.

  →  More for life sciences medical leaders

  →  More for health care suppliers and service firms

Advisory Board At-a-Glance